Nerandomilast (PDE4B inhibitor) joined nintedanib and pirfenidone as FDA-approved options, with each demonstrating reduced FVC decline rates in IPF. Clinical benefit is clearest in progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results